<i>LMNA</i> Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway

<i>LMNA</i> Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway

For patients exhibiting non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a first-line treatment. However, most patients who initially responded to EGFR-TKIs eventually dev...

Full description

Bibliographic Details
Main Authors:	Chunsheng Hu, Anting Zhou, Xin Hu, Yu Xiang, Mengjun Huang, Jiuhong Huang, Donglin Yang, Yan Tang
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	International Journal of Molecular Sciences
Subjects:	<i>LMNA</i> epithelial–mesenchymal transition EGFR-TKI resistance non-small-cell lung cancer
Online Access:	https://www.mdpi.com/1422-0067/23/21/13237

Similar Items

Looking at New Unexpected Disease Targets in <i>LMNA</i>-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice
by: Héléna Mosbah, et al.
Published: (2020-03-01)

Epigenetics in <i>LMNA</i>-Related Cardiomyopathy
by: Yinuo Wang, et al.
Published: (2023-03-01)

Lamin A/C Assembly Defects in <i>LMNA</i>-Congenital Muscular Dystrophy Is Responsible for the Increased Severity of the Disease Compared with Emery–Dreifuss Muscular Dystrophy
by: Anne T. Bertrand, et al.
Published: (2020-03-01)

Nuclear Abnormalities in <i>LMNA</i> p.(Glu2Lys) Variant Segregating with <i>LMNA</i>-Associated Cardiocutaneous Progeria Syndrome
by: Matheus V. M. B. Wilke, et al.
Published: (2024-01-01)

Investigating <i>LMNA</i>-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
by: Yuval Shemer, et al.
Published: (2021-07-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01)

Consequences of <i>Lmna</i> Exon 4 Mutations in Myoblast Function
by: Déborah Gómez-Domínguez, et al.
Published: (2020-05-01)

Mechanisms of A-Type Lamin Targeting to Nuclear Ruptures Are Disrupted in <i>LMNA-</i> and <i>BANF1-</i>Associated Progerias
by: Rhiannon M. Sears, et al.
Published: (2022-03-01)

Can Circulating Cardiac Biomarkers Be Helpful in the Assessment of <i>LMNA</i> Mutation Carriers?
by: Przemyslaw Chmielewski, et al.
Published: (2020-05-01)

<i>LMNA</i> Mutation in a Family with a Strong History of Sudden Cardiac Death
by: Laura Keil, et al.
Published: (2022-01-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
by: Eveline Van De Stadt, et al.
Published: (2022-10-01)

Clinical Spectrum of <i>LMNA</i>-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
by: Antia Fernandez-Pombo, et al.
Published: (2023-02-01)

Atypical Progeria Primarily Manifesting as Premature Cardiac Valvular Disease Segregates with <i>LMNA</i>-Gene Variants
by: Hoi W. Wu, et al.
Published: (2024-03-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
by: Jinyao Zhang, et al.
Published: (2021-12-01)

Partial Lipodystrophy and LMNA p.R545H Variant
by: Silvia Magno, et al.
Published: (2021-03-01)

Revisiting the truncated lamin A produced by a commonly used strain of Lmna knockout mice
by: Joonyoung R. Kim, et al.
Published: (2023-12-01)

Variable Expressivity in Type 2 Familial Partial Lipodystrophy Related to R482 and N466 Variants in the LMNA Gene
by: David Araújo-Vilar, et al.
Published: (2021-03-01)

Characterization of cardiac involvement in children with LMNA-related muscular dystrophy
by: Sergi Cesar, et al.
Published: (2023-03-01)

Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis
by: Melis Sahinoz, et al.
Published: (2018-03-01)

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo <i>MET</i> Amplification in Patients with Metastatic <i>EGFR</i>-Mutated NSCLC
by: Edyta M. Urbanska, et al.
Published: (2023-08-01)

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer Cells
by: Chia-Chi Hsu, et al.
Published: (2021-01-01)

A Family with a Single <i>LMNA</i> Mutation Illustrates Diversity in Cardiac Phenotypes Associated with Laminopathic Progeroid Syndromes
by: Anna-Gaëlle Giguet-Valard, et al.
Published: (2023-09-01)

Modeling of <i>LMNA</i>-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cells
by: Disheet Shah, et al.
Published: (2019-06-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024-01-01)

Uncommon <i>EGFR</i> Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
by: Ilaria Attili, et al.
Published: (2022-01-01)

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
by: Rui Han, et al.
Published: (2020-06-01)

Variable Expressivity and Allelic Heterogeneity in Type 2 Familial Partial Lipodystrophy: The p.(Thr528Met) LMNA Variant
by: David Araújo-Vilar, et al.
Published: (2021-04-01)

Pregnancy and Progression of Cardiomyopathy in Women With LMNA Genotype‐Positive
by: Anna I. Castrini, et al.
Published: (2022-04-01)

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
by: Yuankai Shi, et al.
Published: (2023-01-01)

Novel LMNA Mutation in a Taiwanese Family with Autosomal Dominant Emery-Dreifuss Muscular Dystrophy
by: Wen-Chen Liang, et al.
Published: (2007-01-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for <i>EGFR</i> Mutations in Plasma from Non-Small Cell Lung Cancer Patients
by: Jung-Young Shin, et al.
Published: (2020-11-01)

Activation of sarcolipin expression and altered calcium cycling in LMNA cardiomyopathy
by: Blanca Morales Rodriguez, et al.
Published: (2020-07-01)

Novel linkage of LMNA Single Nucleotide Polymorphism with Dilated Cardiomyopathy in an Indian case study
by: Avinanda Banerjee, et al.
Published: (2015-06-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2023-10-01)

Mandibuloacral dysplasia in a young Vietnamese girl caused by homozygous missense variant c.1579C>T in the LMNA gene with progeria and severe skin lesions
by: Le Huu Doanh, MD, PhD, et al.
Published: (2021-10-01)

<i>LMNA</i> Mutations G232E and R482L Cause Dysregulation of Skeletal Muscle Differentiation, Bioenergetics, and Metabolic Gene Expression Profile
by: Elena V. Ignatieva, et al.
Published: (2020-09-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
by: Wu Z, et al.
Published: (2019-10-01)